Background: Surgical indication for metastatic gastrointestinal stromal tumor (GIST) treated with imatinib is not yet established.
introduction
Once a poorly known entity, gastrointestinal stromal tumor (GIST) has become in these years a leading paradigm for targeted therapies in oncology. Up to 85% of GISTs harbor activating mutations in KIT tyrosine kinase (KIT)/plateletderived growth factor receptor alpha (PDGFRA) genes that drive the tumor development [1] [2] [3] . Imatinib mesylate (formerly STI571, Gleevec/Glivec, Novartis Pharma, Basel, Switzerland) is a selective inhibitor of BCR-ABL tyrosine kinase, KIT and platelet-derived growth factor receptor tyrosine kinases that has demonstrated an exceptional efficacy in GIST and has greatly improved the survival of patients affected by metastatic tumors [4] . Before the imatinib era, the prognosis of these patients was poor with a median survival of 19 months [5] . Owing to the low response rate of GIST to conventional chemotherapy, surgery was the only suitable treatment. At present, imatinib has become the worldwide standard therapy for advanced/metastatic GISTs and its efficacy in terms of progression-free survival (PFS) and disease-specific survival (DSS) has been widely demonstrated [6] [7] [8] [9] [10] [11] . Nevertheless, after an initial response, a secondary resistance to the drug occurs at a median time of 2 years from treatment onset and affects most patients after 4 years [11, 12] . Median survival of metastatic GIST patients treated with imatinib is 5 years [11] . Secondary resistance occurs due to several factors, including the common acquisition of secondary mutations, that confer drug resistance [12] . Many centers have therefore started adding surgery to drug therapy for patients with metastatic GIST. A rationale for carrying out surgery upon best clinical response to imatinib is that a reduction of tumor load might decrease the risk of secondary resistance. Alternatively, one might consider an operation only in case of focal progression with the aim of resecting lesions which have already developed secondary resistance. Both strategies might be pursuable. The present study retrospectively assesses the long-term outcome for patients resected upon one of the two described settings.
materials and methods patients
The study population consists of 80 patients who underwent surgery in the three participating centers (Milan, Mannheim and Robert-Rössle Clinic Berlin, former affiliation of PH and PR) from July 2002 to September 2007. All patients had a previous histopathological diagnosis of GIST, confirmed in terms of morphology and immunophenotype, and were treated with imatinib for primary unresectable, recurrent and/or metastatic GIST. Patients who had received imatinib in clinical trials assessing adjuvant therapy for disease-free individuals (EORTC 62024, SSG-AIO-XVIII) were excluded from the analysis. Patient-and treatment-specific data were extracted from prospectively kept institutional databases and, where needed, complemented through retrospective chart review.
Patients were retrospectively subdivided in two groups. Group A (n = 49) comprises patients who were operated upon clinical response, defined as the absence of progressive disease according to either RECIST or Choi criteria in computed tomography (CT) imaging or magnetic resonance imaging (MRI) [13, 14] . Group B (n = 31) comprises patients in whom surgery was carried out with the aim of resecting single progressive lesions. Patients in general progression who were operated exclusively for debulking or symptomatic palliation were not considered for the present analysis.
Postoperatively, patients went on imatinib or a second-line drug unless intolerability precluded treatment. They were followed up regularly in our outpatient departments through clinical evaluation and CT or MRI scans. Median follow-up was 31 (range 0-57) months in group A and 13 (range 0-76) months in group B. For three patients in group A and five patients in group B, there were no follow-up data available. Thus, survival analyses were restricted to 72 patients.
pathologic and molecular analysis
Assessment of pathologic response was carried out on post-imatinib surgical specimens and was based on microscopic findings. For statistical purposes, patients were divided in two groups according to the presence or absence of viable tumor cells. For molecular analyses, the most representative areas of primary and metastatic tumors were selected. DNA was extracted from formalin-fixed, paraffin-embedded tumors and amplified for KIT and PDGFRA as reported elsewhere [15, 16] . Samples were molecularly characterized by carrying out DNA sequencing of exons 9, 11, 13, 14 and 17 of c-KIT gene and of exons 12, 14 and 18 of PDGFRA.
end points and statistical methods
Groups were compared with regard to patient and treatment characteristics using chi-square statistics for categorical variables, two tailed t-test for age and nonparametric statistics (Wilcoxon rank sum test) for the continuous variable duration of preoperative medical treatment, which was assumed to be not normally distributed. End points were PFS and DSS from the date of surgery and from the date of imatinib onset. Kaplan-Meier survival curves were calculated and log-rank statistics was carried out. Uni-and multivariate Cox regression was carried out for PFS and DSS. For regression analyses, patients for whom c-kit/PDGFR-A mutation data were not available were treated as separate category to avoid them from being excluded from the analyses. In all analyses, P values <0.05 were regarded statistically significant. All statistical analyses were carried out with Stata v 8.1 (The Stata Corporation, College Station, TX).
results patients
The distribution of patients' demographic and clinical characteristics is shown in Table 1 . The only variable for which there are statistically significant differences is c-kit/PDGFR-A mutation. In group A, an exon 11 mutation was detected in significantly more patients than in group B. In both groups, most primary tumors were located in the small bowel. The site of tumor manifestation was distributed roughly similar in both groups. Patients underwent surgery after a median of 15 (range 7-39) months after onset of imatinib treatment in group A and after a median of 21 (range 2-57) months in group B.
All patients except three in group A continued imatinib after surgery. Treatment was restarted after a median time of 10 postoperative days outcomes Surgical morbidity occurred in <20% of patients with no significant differences between the two groups. There was no case of perioperative death (i.e. in-hospital mortality) in the study population. Three patients (group A) required a second operation for postoperative bleeding (one case), intestinal fistula (one case) and evisceration (one case). Median postoperative stay for the whole group was 10 days.
In group A, complete macroscopic surgical removal of the tumor was possible in the majority of cases (88%). At pathologic examination, 31 patients had viable tumor cells. Eighteen (37%) patients showed a complete pathologic In group B, complete macroscopic surgical removal of all the tumor was possible in roughly half of the cases (45%). In the other cases, only the progressing lesion was removed.
Tumor recurrence or progression after surgery developed in 17 patients in group A (34.7%) and in 19 patients in group B (61.3%). Disease-related death occurred in four patients in group A (8.2%) and in nine patients in group B (29.0%). Figure 1 displays the Kaplan-Meier curve for PFS from the time of surgery. In group A, median PFS was not reached; in group B, it was 8 months. Two-year PFS was 64.4% in group A and 9.7% in group B (P < 0.01). Figure 2 displays the KaplanMeier curve for DSS from the time of imatinib onset. Median DSS was not reached in either group. Five-year DSS was 82.9% in group A and 67.6% in group B (P < 0.01).
Among patients who had R2 resection, only two progressed after a median follow-up of 25 months. None of these patients discontinued imatinib after surgery.
Univariate analyses within the single groups did not yield any significant association of PFS and DSS with the variables sex, site of the primary tumor and surgical morbidity (not shown in tables). In group A, all deceased patients had a mutation in exon 11. In group B, deceased patients had a mutation either in exon 11 or in exons other than 9 or 11 or multiple mutations. Therefore, the analyses could not provide any risk estimates for exon 9 mutation or wild type. Tables 2 and 3 display the results of univariate and multivariate Cox regression analyses of both groups jointly for PFS and DSS. With the exception of c-kit/PDGFR-A mutation in the univariate analysis of DSS, the only statistically significant determinant of both PFS and DSS is the study group, with patients in group B, i.e. those who underwent surgery upon focal progression, having significantly higher hazards of subsequent disease progression and disease-specific death. The magnitude of the association is very large with hazard ratios of 10.85 and 13.51, respectively. discussion This analysis focuses on the outcome of a large series of patients who underwent surgical resection of metastatic or recurrent GIST upon best clinical response or focal progression following imatinib therapy. The intention of the surgical procedure was to remove either the whole tumor bulk to prevent subsequent Secondary resistance to imatinib is the main complication that limits the long-term efficacy of this drug. Such resistance is related to several factors, including pharmacokinetic alterations and acquired mutations that become clinically relevant after prolonged exposure [17] . This fact provides a rationale for the usefulness of surgery as part of a multimodal approach for the treatment of metastatic GIST. Given its mechanism of action, it is clear that despite high clinical efficacy, imatinib does not reach a complete pathologic response as potentially do 'conventional' cytotoxic drugs [18] . The clinical consequence is that the interruption of therapy almost inevitably leads to reoccurrence or progression of disease. This was demonstrated in a large phase III study by the French Sarcoma Group [19] . Given the inability of imatinib to induce a complete and durable response, surgical resection seems the only suitable option to definitively eradicate the tumor. The worst consequence of this disease persistence is that GISTs frequently develop secondary resistance which likely results from selection or evolution of mutant cells. Surgery could either prevent this event if carried out early or remove resistant tumor tissue if carried out upon clinical progression. So far, it has not been clear if the theoretical usefulness of surgery indeed leads to a clinical benefit and, if so, which is its best timing.
Secondary progression usually occurs after 2 years. On the other hand, further tumor response can occur even months after the start of imatinib. If surgery is carried out too early, complete resection of all tumor tissue might not be possible, whereas if it is timed too late, secondary resistance might have already developed. In our study, the median time from the beginning of imatinib treatment to surgery was 15 months in the group with clinical response and 21 months in the group with progressive disease. In the latter group, patients were readily operated very soon after disease progression had been diagnosed, which roughly speaking means that progression frequently occurred between 15 and 21 months after treatment had been started. Consequently, it can be postulated that in most cases, surgery should not take place much later than 1 year after imatinib onset if a clinical response is achieved.
Some retrospective studies, on smaller series, have already reported a favorable outcome for responsive patients undergoing surgery following imatinib therapy [20] [21] [22] [23] [24] [25] . For patients in our study operated upon the best response, PFS and DSS were longer than in a recent trial evaluating imatinib treatment without surgery for metastatic or recurrent GIST [11] . In our series, in group A, 5-year DSS was 82.9% compared with 55% for patients who reached SD or responsive disease in the trial. This might indicate that the long survival achieved in this subgroup of patients is an effect of the combination of imatinib and surgery, rather than a selection of better patients that would have had the same outcome even with imatinib alone. In another phase III study comparing interruption versus continuation of imatinib treatment beyond 1 year, Blay et al. [19] report an estimated 2-year PFS of <30% from randomization, i.e. from 1 year after having started imatinib, in the group of patients who continued the drug. Median PFS was 18 months from randomization. In this study, patients were selected for randomization only if they had reached SD or objective tumor response for at least 12 months. Therefore, this series is more similar to our group A, where 2-year PFS from surgery, which in turn took place after a median of 15 months after having started imatinib treatment, was 64.4%. However, our patients were all judged resectable, whereas in the other series, only 7% of patients were considered suitable for surgery by a multidisciplinary tumor board. Such direct comparisons between studies have to be interpreted with much caution since they are prone to bias originating from potential differences in the study populations. Given the design of our study, it remains difficult to discriminate whether the survival advantage we observed in patients operated upon clinical response is due to the timing of surgical procedure or selection bias. Since patients selected for surgery probably were the ones with better performance status, inferior tumor load and long-lasting good response to treatment, selection bias is rather likely. To answer the question of the utility of surgery in the described setting, randomized studies are strongly needed. In Europe, an international, intergroup European Organization for Research and Treatment of Cancer randomized phase III trial will be opened in the near future.
As far as patients with focal progression are concerned, in our study, 61.3% showed progression after a median of eight postoperative months and 44 months after starting imatinib therapy. Two-year PFS and DSS from surgery was 9.7% and 69.5%, respectively. These data are comparable to the results obtained by second-line tyrosine kinase inhibitors [26] . Since second-line therapies are often not as well tolerated as imatinib, surgery could be regarded as a useful option in patients with good performance status and surgically favorable tumor site as well as in those tolerating second-line drugs badly.
One argument often brought forward against surgery in metastatic or recurrent GIST is that potential complications outweigh the rather small clinical benefit in terms of survival. In our series, however, the rate of severe surgical morbidity was low. This is comparable to results of a similar series [22] . Specifically, since the rate of complications seems to be in the range known from large abdominal operations in other oncological patients, there is no strong reason to assume that previous treatment with imatinib would lead to an increased morbidity.
conclusions
Patients who undergo surgery for focal progressive disease have a limited benefit in terms of disease control. Surgery seems not to prevent generalized progression in most patients but could be considered as part of the second-line/third-line armamentarium in selected cases.
Surgery of residual disease upon best clinical response conveys a survival benefit compared with historical controls in similar patient collectives treated with imatinib alone. However, comparisons across different studies are prone to bias and therefore only partially valid. Since our study had a nonrandomized retrospective design, selection bias, i.e. that patients with a per se better prognosis had a higher chance of being selected to receive surgery, is rather likely. Therefore, evidence from prospective randomized trials is strongly needed in order to make definite recommendations if and when surgery should be carried out. 
